prospective patients have to fall within a pretty strict criteria. I believe that's the only reason IMO. After we see good results, I'm sure the criteria could be broadened. But for now it's a design that should show NVIV can help improve the problem and to allow the FDA to measure the effects / improvement. We all hate waiting but hopefully when we finally start, we hit a homerun. All IMO, GLTA longs and future patients. Keep in mind the best spinal surgeons in the country are involved in this study / trial, patience will be important until we get the first patient.
News 
Market Data 
Discover 
